共 50 条
- [1] Efficacy and safety of risankizumab therapy in Chinese patients with moderately to severely active crohn's diseaseJOURNAL OF CROHNS & COLITIS, 2025, 19 : i1298 - i1299Gao, X.Cao, Q.Ran, Z. H.Chen, Y. X.Chen, Y.Wen, Z. H.Liu, D. L.Ding, J.Zhong, J.Liu, F.Sha, W. H.An, P.Wang, B. M.Hu, L. X.
- [2] Efficacy and safety of upadacitinib in patients with moderately to severely active Crohn's disease: results from the U-ENDURE long-term extensionJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 161 - 162Mitrev, NikolaD'Haens, GeertLouis, EdouardLoftus, Edward, Jr.Regueiro, MiguelJairath, VipulMagro, FernandoNakase, HiroshiDubcenco, ElenaLacerda, AnaFeng, TianDuncan, BenjaminWang, TaoFord, SharanyaAnyanwu, SamuelBlumenstein, Irina
- [3] Efficacy and safety of upadacitinib in patients with moderately to severely active Crohn's Disease: results from the U-ENDURE long-term extensionJOURNAL OF CROHNS & COLITIS, 2024, 18 : I17 - I18D'Haens, G.Louis, E.Loftus, E. V.Regueiro, M.Jairath, V.Magro, F.Nakase, H.Dubcenco, E.Lacerda, A. P.Feng, T.Duncan, B.Wang, T.Ford, S.Anyanwu, S. I.Blumenstein, I.
- [4] Efficacy and safety of upadacitinib in patients with moderately to severely active Crohn's Disease: results from the U-ENDURE long-term extensionSWISS MEDICAL WEEKLY, 2024, 154 : 2S - 2SD'Haens, G.Louise, E.Loftus, E. V., Jr.Regueiro, M.Jairath, V.Magro, F.Nakase, H.Dubcenco, E.Lacerda, A. P.Feng, T.Duncan, B.Wang, T.Ford, S.Anyanwu, S. I.Juilleratm, P.Blumenstein, I.
- [5] Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease With 3 Years of Treatment: Results From the FORTIFY Open-Label Long-Term ExtensionJOURNAL OF CROHNS & COLITIS, 2025, 19 : i109 - i111Ferrante, M.Panaccione, R.Colombel, J. F.Dubinsky, M. C.Hisamatsu, T.Lindsay, J. O.Song, A.Yao, Y.Zhang, Y.Zambrano, J.Aponte, F.Duan, W. R.D'Haens, G.
- [6] Long-term Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease up to 3 Years of Treatment: Results From the FORTIFY Open-Label Long-term ExtensionJOURNAL OF CROHNS & COLITIS, 2024, 18 : I167 - I169Ferrante, M.Panaccione, R.Colombel, J. F.Dubinsky, M.Hisamatsu, T.Lindsay, J. O.Song, A.Neimark, E.Zhang, Y.Kligys, K.Crowley, J.Duan, W. R.D'Haens, G.
- [7] Efficacy and Safety of Upadacitinib Maintenance Treatment in Patients With Moderately to Severely Active Crohn's Disease: Two Year Results From the U-ENDURE Long-Term Extension StudyAMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S737 - S739D'Haens, Geert R.Louis, EdouardLoftus, Edward V.Regueiro, Miguel D.Jairath, VipulMagro, FernandoNakase, HiroshiDubcenco, ElenaLacerda, Ana PaulaFeng, TianDuncan, BenjaminWang, TaoAnyanwu, SamuelAponte, FernandoBlumenstein, Irina
- [8] EFFICACY AND SAFETY UP TO THREE YEARS OF RISANKIZUMAB TREATMENT IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE FORTIFY OPEN-LABEL LONG-TERM EXTENSIONGASTROENTEROLOGY, 2024, 166 (05) : S801 - S802Ferrante, MarcPanaccione, RemoColombel, Jean FredericDubinsky, Marla C.Hisamatsu, TadakazuLindsay, James O.Song, Alexandra P.Neimark, EzequielZhang, YingKligys, KristinaCrowley, JamesonDuan, W. RachelD'Haens, Geert
- [9] USTEKINUMAB IN PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE UNISTAR STUDY LONG-TERM EXTENSIONGASTROENTEROLOGY, 2023, 164 (06) : S1185 - S1185Rosh, Joel R.Turner, DanCohen, Stanley A.Griffiths, Anne M.Hyams, Jeffrey S.Kierkus, JaroslawAdedokun, Omoniyi J.Strauss, RichardKim, LilianneVolger, Sheri
- [10] Ustekinumab in paediatric patients with moderately to severely active Crohn's disease: Results from the UniStar study long-term extensionJOURNAL OF CROHNS & COLITIS, 2023, 17 : 802 - 803Turner, D.Rosh, J. R.Cohen, S. A.Griffiths, A.Hyams, J. S.Kierkus, J.Adedokun, O. J.Strauss, R.Kim, L.Volger, S.